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Background: Apoptosis is one of the presumptive causes of CD4+ T cell depletion during HIV infection and
progression to AIDS. However, the precise role of HIV-1 in this process remains unexplained. HIV-1 protease (PR) has
been suggested as a possible factor, but a direct link between HIV-1 PR enzymatic activity and apoptosis has not
been established.
Results: Here, we show that expression of active HIV-1 PR induces death in HeLa and HEK-293 cells via the
mitochondrial apoptotic pathway. This conclusion is based on in vivo observations of the direct localization of HIV-1 PR
in mitochondria, a key player in triggering apoptosis. Moreover, we observed an HIV-1 PR concentration-dependent
decrease in mitochondrial membrane potential and the role of HIV-1 PR in activation of caspase 9, PARP cleavage and
DNA fragmentation. In addition, in vitro data demonstrated that HIV-1 PR mediates cleavage of mitochondrial proteins
Tom22, VDAC and ANT, leading to release of AIF and Hsp60 proteins. By using yeast two-hybrid screening, we also
identified a new HIV-1 PR interaction partner, breast carcinoma-associated protein 3 (BCA3). We found that BCA3
accelerates p53 transcriptional activity on the bax promoter, thus elevating the cellular level of pro-apoptotic Bax
protein.
Conclusion: In summary, our results describe the involvement of HIV-1 PR in apoptosis, which is caused either by a
direct effect of HIV-1 PR on mitochondrial membrane integrity or by its interaction with cellular protein BCA3.
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A major determinant of pathogenicity in untreated human
HIV-1 infection is depletion of CD4+ T cells, caused in
large part by apoptosis (reviewed in [1-4]). Six HIV-1-
encoded proteins—surface glycoprotein (gp120), Tat, Nef,
Vpr, Vpu and protease (PR)—have been shown to induce
apoptosis [1-3,5-8]. During HIV-1 infection, the virus-
encoded aspartic PR is expressed as part of the Gag-Pol
polyprotein precursor. The Gag polyprotein comprises the
structural proteins of the viral shell (matrix, capsid and
nucleocapsid), while the Pol polyprotein consists of viral
PR, reverse transcriptase and integrase. Upon expression,
the polyprotein precursors Gag and Gag-Pol migrate to
the plasma membrane, where they assemble into imma-
ture viral particles. During or shortly after budding of an* Correspondence: rumlova@uochb.cas.cz
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unless otherwise stated.immature HIV-1 particle, the protease self-activates and is
released from its precursor. The active PR then cleaves
polyprotein precursors into mature proteins. Despite
widely accepted opinion that retroviral proteases are acti-
vated during virus budding, specific processing of HIV-1
polyproteins has been identified also in the membrane
fraction and cytoplasm of HIV-1-infected cells, suggesting
that some PR activation takes place within the cells before
Gag reaches the plasma membrane [9].
Expression of HIV-1 PR is cytotoxic for transfected cells
[10-12]. Although several cellular proteins, such as actin
[13], laminin [14], vimentin [15,16], Bcl-2 [11], eukaryotic
initiation factor 4G [17], procaspase 8 [18-20], PABPC1
[21] and a subunit of eukaryotic translation factor 3
(eIF3d) [22], can be cleaved by HIV-1 protease, the precise
mechanism of cell death caused by HIV-1 PR is still un-
clear. The first suggested mechanism was direct cleavage
of the anti-apoptotic protein Bcl-2 by HIV-1 PR, leading
to cell death via apoptosis [11]. However, this was not
confirmed in subsequent studies [12,18,22]. Morpho-
logical changes typical of necrosis—but no apoptosisal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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HIV-1 PR [12]. Another mechanism proposed for HIV-1
PR-mediated apoptosis was based on the observation that
PR cleaves caspase 8 both in vitro and in vivo to yield a
novel Casp8p41 fragment [18,19]. Two mechanisms of
potential Casp8p41-initiated caspase-dependent cell death
have been proposed: (i) Casp8p41 mediates activation of
pro-apoptotic protein Bid by cleaving it to form tBid [18]
and (ii) Casp8p41 independently induces apoptosis by
interacting with mitochondria, resulting in rapid Bax/Bak
mediated mitochondrial depolarization [19,23,24]. In both
proposed mechanisms, cytochrome c is released from
mitochondria, caspase 9 and 3 are activated and the cell is
directed to its death.
Breast carcinoma-associated protein 3 (BCA3, a proline-
rich protein also known as A-kinase interacting protein or
AKIP1) was first identified and characterized in breast and
prostate cancer cell lines [25,26]. The full-length transcript
consists of six exons, with a translation start in exon 2.
However, several BCA3 splice variants have been identi-
fied in various cell lines [26,27]. Although BCA3 has been
reported to interact with various cellular proteins (e.g.
cAMP-dependent protein kinase A (PKAc) [27], NFκB
[28-30], p73 [31], apoptosis inducing factor (AIF) [32]) its
precise cellular role remains unclear.
Here, we report that BCA3 acts as a novel HIV-1 PR
binding partner. We show that HIV-1 PR is localized in
the mitochondria of HEK-293 and HeLa cells, where it in-
teracts with BCA3. We also show that expression of HIV-1
PR in HEK-293 and HeLa cells most likely leads to cell
death via the intrinsic mitochondrial apoptotic pathway.
We based this conclusion on several observations: (i)
direct localization of HIV-1 PR in the mitochondria;
(ii) in vitro cleavage of mitochondrial proteins, such as the
receptor for the outer membrane translocase complex
(Tom22), voltage-dependent anion channel (VDAC) and
adenine nucleotide translocator (ANT), leading to release
of pro-apoptotic mitochondrial proteins; (iii) HIV-1 PR
concentration-dependent decrease in mitochondrial mem-
brane potential (ΔΨm) and (iv) activation of caspase 9
(Casp-9), poly-(ADP-ribose)-polymerase (PARP) cleavage
and DNA fragmentation. HIV-1 PR-induced apoptosis is
enhanced by BCA3, which enhances p53 transcriptional
activity on the bax promoter.
Results
HIV-1 PR interacts with BCA3
Using a yeast two-hybrid system, we identified BCA3 as a
novel binding partner of Mason-Pfizer monkey virus pro-
tease (M-PMV PR) [33]. As three-dimensional structures
of retroviral proteases share certain conserved features
[34,35], we analyzed the ability of catalytically inactive
HIV-1 PR(D25N) to bind to BCA3. Co-immunoprecipita-
tion experiments of the cell expressing M-PMV or HIV-1PRs together with BCA3 (Figure 1a) clearly showed that
besides both forms of M-PMV PRs, i.e., PR17(D26N) and
PR12(D26N), (Figure 1b, lanes 2,3,6,7) also HIV-1 PR
(D25N) directly interacts with BCA3 in HeLa and HEK-
293 cells (Figure 1b, lanes 4,8).
We used confocal microscopy to confirm these results
(Figure 1c). Immunofluorescence staining showed that
HA-BCA3 was localized mainly in the cytoplasm and
partially within the nucleus of HEK-293 cells, whereas
HIV PR was localized only within the cytosol in a speckled
pattern. Co-expressed BCA3 and HIV-1 PR co-localized
in the cytoplasm (Figure 1c, lower panels).
Mitochondrial localization of BCA3 and HIV PR
We next analyzed whether localization of HIV-1 PR –
BCA3 complex corresponds to a particular subcellular
compartment. HeLa cells were co-transfected with expres-
sion vectors encoding mitochondrial (Mito-GFP, Mito-
dsRed) or endoplasmic reticulum (ER-GFP) markers and
HA-BCA3 or c-myc-HIV-1 PR(D25N). Localization of the
proteins was analyzed using fluorescent microscopy. Both
BCA3 and HIV-1 PR(D25N) proteins were identified in
the mitochondria (Figure 2a). To further confirm their
mitochondrial localization, HEK-293 or HeLa cells co-
expressing HA-BCA3 and c-myc-HIV-1 PR(D25N) were
analyzed. Western blot analysis confirmed the presence of
BCA3 and HIV-1 PR(D25N) in the main mitochondrial
fraction of iodixanol gradient (Figure 2b). Immunogold
transmission electron microscopy (TEM) also confirmed
the presence of both BCA3 and HIV-1 PR(D25N) mainly
at the mitochondria (Figure 2c). In contrast to the control
mitochondrial protein voltage-dependent anion channel
(VDAC), which was present exclusively at the mitochon-
drial surface, the BCA3 and HIV-1 PR(D25N) proteins
were also localized at membrane invaginations reminis-
cent of cristae. Co-immunoprecipitation of BCA3 with
HIV-1 PR(D25N) from mitochondrial fractions confirmed
the interaction of these two proteins in the mitochondrial,
but not in the cytosolic fractions (Figure 2d,e).
Detailed analysis of the composition of the mitochon-
drial fractions containing BCA3 and HIV-1 PR(D25N)
verified the presence of several mitochondrial proteins,
including Mito-marker (Abcam), VDAC, cytochrome C
(COXIV), receptor of the outer membrane translocase
complex (Tom22) and Bax (Additional file 1: Figure S1a).
We also verified that the mitochondrial localization of
HIV-1 PR(D25N) is not an artifact caused by structural
changes introduced either by the active site mutation
(D25N) or the N-terminal extension by c-myc/HA tags.
The association of these HIV-1 protease variants with
mitochondria was confirmed by Western blot analysis
of mitochondria isolated from cells producing inactive
(D25N) and active HIV-1 PR, and N-terminally extended
PR with native flanking sequence, i.e. HIV-1 PRO in the
Figure 1 Interaction of M-PMV PR, HIV-1 PR and BCA3. (a) Western blot analysis of total lysates of the HEK-293 cells transfected with c-myc-M-PMV
PR17(D26N), c-myc-M-PMV PR12(D26N), c-myc-HIV-1 PR(D25N) and HA-BCA3. The blots were developed with anti c-myc (upper panel) and HA (lower
panel) antibodies. (b) Co-immunoprecipitation of M-PMV or HIV PRs with BCA3: HEK-293 (lanes 1–4) and HeLa (lanes 5–8) cells transfected with
c-myc-M-PMV PR17(D26N), c-myc-M-PMVPR12(D26N) or c-myc-HIV-1 PR(D25N) together with HA-BCA3 were lysed 48 h post-transfection, and proteins
were immunoprecipitated using anti-c-myc antibody. Precipitates were blotted and developed with anti-c-myc (upper panel) or anti-HA (lower panel)
antibodies. (c) Immunocolocalization of HIV-1 PR(D25N) with BCA3 in HEK-293 cells using confocal microscopy: HEK-293 cells transfected with
c-myc-HIV-1 PR(D25N) together with HA-BCA3 were stained 48 h post-transfection using anti HA-TRITC or c-myc-FITC antibodies and visualized using
confocal microscopy. The two black panels represent the samples of the cells not producing BCA3 (first row) and HIV-1 PR (second row) demonstrating
thus that HA-TRITC and c-myc-FITC antibodies do not provide non-specific signal.
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presence of HIV-1 PR(D25N)/BCA3 complex in endo-
plasmic reticulum was excluded (Additional file 1: Figure
S1d). Next we verified that the HIV-1 PR interacts also
with endogenous BCA3. Because the endogenous level of
expression of BCA3 is under detection limit of commer-
cially available antibodies, we prepared stably transfected293-HEK cell line (labelled D1) in which the level of
HA-BCA3 expression is significantly lower than in tran-
siently transfected cells. These cells were transfected with
c-myc-HIV-1 PR (D25N) or c-myc-HIV-1 PRO (D25N) and
co-immunoprecipitations using c-myc and HA antibodies
were carried out. Western blot analysis confirmed that
both HIV-1 PR and HIV-1 PRO interacted with BCA3
Figure 2 Mitochondrial localization of HIV-1 PR and, BCA3. (a) HeLa cells were co-transfected with c-myc-HIV-1 PR(D25N), or HA-BCA3 and
mitochondrial marker pDsRed2-Mito. HeLa cells were stained 48 h post-transfection using anti-HA-TRITC or c-myc-FITC antibodies and visualized
using confocal microscopy. Mitochondria were stained red; the overlaid images show colocalization of mitochondrial marker with BCA3 and HIV-1
PR(D25N), as well as HIV-1 PR(D25N) with BCA3. (b) Purified mitochondria from HeLa cells transfected with c-myc-HIV-1 PR(D25N), HA-BCA3, or a
combination of c-myc-HIV-1 PR(D25N) with HA-BCA3. Fractions from Optiprep gradient (labeled 1–12) were analyzed using Western blot with
Mitochondrial Marker antibody and anti-HA and anti-c-myc antibodies. (c) Immunogold TEM analysis of localization of VDAC (left panels, bar
represents 500 nm), BCA3 (middle panels, bar represents 500 nm) and HIV-1 PR(D25N) (right panels, bar represents 1 μm) in HEK-293 cells.
(d,e) Western blot (d) and co-immunoprecipitation followed by Western blot analysis (e) of HIV-1 PR(D25N) and BCA3 present in cytosolic and
mitochondrial fractions. HEK-293 cells (4x105 cells/ml) were co-transfected with HA-BCA3 and c-myc-HIV-1 PR(D25N). After 48 h, the cells were
washed 1× with PBS and 1/20 of the cells was resuspended in PLB and used as a total cell lysate sample for Western blot analysis (d, lane 1). 1/4
of the cells were used for immunoprecipitation (e, lane 4) using anti-HA and anti-c-myc antibodies. The last 3/4 of the cells was used for the
isolation of cytosolic and mitochondrial fractions. 100 μl aliquots of both cytosolic and mitochondrial fractions were analyzed using Western blot
(d, lanes 2 and 3, respectively) and 900 μl aliquots of both cytosolic and mitochondrial fractions samples were used for immunoprecipitation
using anti-HA and anti-c-myc antibodies and developed by Western blot (e, lanes 5 and 6).
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Figure S1e).
Sublocalization of HIV-1 PR(D25N)/BCA3 complex in
mitochondria
To define the submitochondrial localization of the HIV-1
PR/BCA3 complex, mitochondria isolated from HEK-293/HeLa cells transfected with c-myc-HIV-1PR(D25N) and
HA-BCA3 were treated with increasing amounts of
proteinase K (PK; 0.14, 1.4, and 14 μM) in the presence
or absence of Triton X-100. We also determined the
accessibility of PK to selected proteins localized: i) at the
cytoplasmic site of the outer mitochondrial membrane
(OMM), i.e., Bak, Mito-marker (Abcam) and Tom22; ii) in
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membrane (IMM), i.e., COXIV. At the lowest concen-
tration, PK completely degraded Bak and Mito-marker
(Abcam), whereas Tom22, which is likely to be protected
by its close association with other Tom proteins was par-
tially degraded only in the presence of detergent (Figure 3a).
However, at the higher concentration (1.4 μM), PK ef-
ficiently degraded not only Tom22 but also VDAC
(Figure 3b). The IMM-localized COXIV protein was re-
sistant, and its complete degradation by PK was observed
only at the highest PK concentration (Figure 3c). Similarly,
BCA3 and HIV-1 PR(D25N) were degraded only at PK
concentrations of 1.4 μM and higher (Figure 3b), sug-
gesting their localization inside in the mitochondria.
This result is in agreement with the immunogold TEM
(Figure 2c) which also suggested that HIV-1 PR(D25N)
and BCA3 are associated with the inner mitochondrial
membrane.
Expression of HIV-1 PR triggers mitochondrial apoptosis
To determine whether the increased cell death induced by
expression of catalytically active HIV-1 PR (Figure 4a) can
be attributed to apoptosis, either HeLa or HEK-293 cells
were transfected with various amounts of c-myc-HIV-1
PR, and their progression to apoptosis was determined
as described in Materials and Methods. Six hours post-
transfection, we observed an HIV-1 PR concentration-
dependent increase of a number of annexin-V-positive
apoptotic cells (Figure 4b,c) and a protease-concentration-
dependent decrease in mitochondrial membrane potential
ΔΨm (Figure 4d,e). We also observed fragmentation of
nuclear DNA in HEK-293 cells transfected with c-myc-
HIV-1 PR, characteristic of the late phase of apoptosis
(Figure 4f).
Our finding that HIV-1 PR is associated with mitochon-
dria and causes apoptosis accompanied with a loss ofFigure 3 OMM localization of HIV-1 PR and BCA3. Purified mitochondri
HA-BCA3 were incubated with 0.14 μM (a), 1.4 μM (b) or 14 μM (c) protein
ice. The reaction was stopped by the addition of 6× protein loading bufferΔΨm suggested its direct involvement in mitochondrial
membrane permeabilization (MMP), typical for the in-
trinsic mitochondrial pathway of apoptosis. Therefore, we
next analyzed the impact of HIV-1 PR on selected anti-
and pro-apoptotic Bcl-2 family proteins involved in mito-
chondrial outer membrane permeabilization (MOMP)
using: (i) in vivo cleavage of cellular proteins in HeLa or
HEK-293 cells producing catalytically active HIV-1 PR
(Figure 5a) and (ii) in vitro cleavage of whole HeLa
or HEK-293 cell extracts by recombinant HIV-1 PR
(Figure 5b). First we confirmed that PR was active, as its
natural substrate Gag polyprotein was efficiently cleaved to
capsid protein (CA) both in cells transfected with c-myc-
HIV-1 PR (Figure 5a) and in cell lysates by using recom-
binant PR (Figure 5b). The profile of HIV-1 PR-mediated
cleavage of selected cellular proteins was similar for both
approaches (compare Figure 5a and b). The BCA3 protein
was not degraded by HIV-1 protease either in vitro or
in vivo. Neither had we observed any cleavage of anti-
apoptotic molecule Bcl-2, pro-caspase 8 cleavage to
Casp8p41 nor Bid truncation to tBid. In contrast, both
in vivo and in vitro, we identified the activation of pro-
caspase 9 to caspase 9 (Casp-9) (Figure 5a,b) which occurs
only in response to cytochrome c release from mitochon-
dria. Cleavage of poly(ADP-ribose) polymerase (PARP),
occurring in the late phase of apoptosis upon activation of
caspase 3, was also observed (Figure 5a,b). Moreover, we
identified in vitro cleavage of the pro-apoptotic protein Bax
(p21) to its lower molecular weight form (Figure 5b). It has
been shown that such N-terminal cleavage of p21Bax, me-
diated by cysteine protease calpain to yield p18Bax, occurs
during stress-induced apoptosis [36-39]. To study whether
HIV-1 PR may also trigger or enhance Bax cleavage, either
HEK-293 or HeLa cell extracts were treated with recom-
binant HIV-1 PR, with or without an HIV-1 protease-
specific inhibitor (ritonavir) or calpain protease inhibitor I.a from HEK-293 cells co-transfected with c-myc-HIV-1 PR(D25N) and
ase K in the presence or absence of Triton X-100 for 10 and 60 min on
(PLB), and samples were analyzed by Western blotting.
Figure 4 Apoptotic effect of HIV-1 PR. (a) Cytotoxic effect of
HIV-1 PR on HeLa cells. HeLa cells were transfected with c-myc-HIV-1
PR (1 μg/ml), encoding catalytically active HIV-1 PR and the number
of dead cells at various post-transfection time points was assessed
by PI staining by flow cytometry using BD LSR Fortessa. (b) HeLa
cells were transfected with indicated amounts of c-myc-HIV-1 PR. Six
hours post-transfection, the cells were labeled with FITC Alexa Fluor®
488 annexin V and propidium iodide (PI), and the apoptotic + dead
cells were detected using BD LSR Fortessa. (c) Representative gating
for control and HIV-1 PR expressing cells. (d) The HEK-293 cells were
transfected with varying amounts of c-myc-HIV-1 PR. Changes in ΔΨm
were determined six hours post-transfection by staining with JC-1
fluorochrome followed by flow cytometry using BD LSR Fortessa.
(e) Representative gating for control and HIV-1 PR expressing cells.
Healthy cells containing red JC-1 aggregates were detected in the FL 2
channel, whereas green JC-1 monomers in apoptotic cells were
monitored in the FL1 channel (FITC). (f) HEK-293 cells were transfected
with c-myc-HIV-1 PR, and 24 h post-transfection, fragmented DNA was
isolated using the Suicide-TrackTM DNA Ladder Isolation Kit and
separated by agarose gel. The mean percentage (±standard deviation)
of the data pooled from three independent experiments is shown.
Each data point was repeated at least twice.
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was processed to its p18Bax form and then degraded
during long incubations (Figure 5c, lane 4 h). Ritonavir that
efficiently blocked HIV-1 PR (Figure 5d) did not inhibit
calpain protease, (Figure 5d). However, ritonavir blocked
complete degradation of p18Bax by residual calpain from
the cell lysate (compare lanes corresponding to 4 h of
incubation in Figure 5c,d). Calpain protease inhibitor I did
not inhibit Gag processing by HIV-1 PR but completely
blocked Bax cleavage (Figure 5e). No HIV-1 PR cleavage of
Bak or Bid proteins was observed. Interestingly, activation
of caspase 9 occurred only in samples containing active
HIV-1 PR (Figure 5c,e). This data suggests that, under
in vitro conditions, calpain protease cleaves p21Bax to
p18Bax and HIV-1 PR subsequently cleaves p18Bax but
not p21Bax protein. To verify this hypothesis, the bax gene
was isolated from a HeLa cell cDNA library and genes
encoding wild-type p21Bax and p18Bax were cloned under
transcriptional control of T7 bacteriophage promoter. Both
proteins were synthesized using an in vitro transcription/
translation system and subjected to proteolysis by HIV-1
PR in the presence or absence of ritonavir. In contrast to
p21Bax, which was not cleaved by HIV-1 PR, the truncated
p18Bax was degraded (Figure 5f).
The activation of caspase 9 and cleavage of PARP were
the only changes directly affected by the presence of HIV-1
PR (Figure 5a-e). We next analyzed whether there is any
direct proteolytic action of HIV-1 PR on purified mi-
tochondria. Isolated mitochondria were treated with va-
rious amounts of recombinant HIV-1 PR, and selected
mitochondrial proteins were analyzed by Western blot
(Figure 5g). We observed increased proteolytic processing
of the OMM proteins such as Tom22 and VDAC, as well
as IMM-localized ANT in an HIV-1 PR concentration-
Figure 5 Proteolytic processing of cellular proteins by active HIV PR. (a) HEK-293 cells transfected with HIV-1 Gag and HA-BCA3 (500 ng
each) and various amounts of c-myc-HIV-1 PR (25–1000 ng) were analyzed 48 h post-transfection. (b-e) HEK-293 cells transfected with HIV-1 Gag
and HA-BCA3 were lysed 48 h post-transfection as described in Materials and Methods and incubated with recombinant HIV-1 PR (1.25 μM),
optionally in the presence of ritonavir (4 μM) (d) or calpain inhibitor I (100 μM) (e) at 37°C for the time indicated. The proteins were then separated on
12-15% SDS-PAGE and analyzed by Western blot. (f) Autoradiographic analysis of HIV-1 PR in vitro cleavage of full-length p21Bax and N-terminally
truncated p18Bax proteins obtained by TNT transcription/translation system. Protein samples were treated with HIV-1 PR (1.25 μM), optionally in the
presence of ritonavir (8 μM), at room temperature for the time indicated. The proteins were then separated on 15% SDS-PAGE and visualized by
autoradiography. (g) In vitro cleavage of mitochondrial proteins by HIV-1 PR. Freshly isolated mitochondria from HEK-293 cells were incubated with
various amounts of recombinant HIV-1 PR, optionally in the presence of ritonavir (4 μM). The proteins in the samples were separated on 12-15%
SDS-PAGE and analyzed by Western blot. (h) Supernatant after cleavage of proteins from purified mitochondrial fraction. The samples from (g) were
centrifuged, and supernatants were analyzed by Western blot.
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causes release of mitochondrial proteins involved in
apoptosis, purified mitochondria were incubated with
various amounts of HIV-1 PR in the presence or ab-
sence of ritonavir. The mitochondria were then pelleted
and selected proteins released into supernatant were
analyzed by Western blot. Specifically, apoptotic indu-
cing factor (AIF) and Hsp-60 were released into the
supernatant (Figure 5h).BCA3 enhances transcriptional activity of p53 on the bax
promoter
BCA3 affects the activity of transcription factor p73,
which is a p53 homologue [31]. As the p53 tumor sup-
pressor is known to be a direct activator of the bax gene
promoter [11,40], we examined whether BCA3 could
regulate the bax promoter by modulating its transcrip-
tion by p53. The pGL3-bax-luc reporter vector encoding
a luciferase gene under control of the bax promoter was
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plasmid DNA and various amounts of HA-BCA3 plas-
mid (25–100 ng). Luciferase activity was measured 24–
48 h post-transfection. As shown in Figure 6a, BCA3
had a dose-dependent activation effect on p53-induced
transcriptional activity of bax promoter. Addition of
c-myc-HIV-PR(D25N) increased bax promoter activation
compared to expression of BCA3 alone (Figure 6b). To
analyze whether BCA3 could activate endogenous p53
and thus enhance the level of Bax protein, we performed
Western blot analysis of HEK-293 cells transfected with
various amounts of HA-BCA3. BCA3 enhanced ex-
pression of p53, Bax and an acetylated form of p53 [41]
(Figure 6c). As it is well-established that p53 rapidly
translocates to mitochondria in response to stress signals
[42], we isolated and analyzed nuclear and mitochondrial
fractions from HEK-293 cells expressing increasing
amounts of BCA3. As expected, the BCA3 protein was
identified in isolated mitochondrial fractions (Figure 6d,e).
However, we did not observe increased concentration of
p53 in the mitochondrial fraction, but rather in the
nuclear fraction (Figure 6d). Apoptosis was increased in
the cells co-transfected with c-myc-HIV-1 PR and HA-
BCA3 in contrast to those transfected with only c-myc-
HIV-1 PR or HA-BCA3 (Figure 6f ). The p value was
calculated by using Tukey Honest Significant Difference
test. The test has shown insignificant difference (p < 0.47)
between HIV-1 PR and BCA3 (columns 1 and 2 in
Figure 6f ). Importantly, the effect HIV-1 PR + BCA3
expression on apoptosis was statistically significant,
characterized by p < 0.0047547 and p < 0.0015748 for the
cells expressing HIV-1 PR and BCA3, respectively. Thus,
BCA3 seems to contribute to apoptosis induced by HIV-1
PR.
Discussion and conclusions
It has been suggested that depletion of CD4+ T cells in-
duced by HIV-1 is associated with a change in mitochon-
drial permeability that leads to cellular apoptosis [5,43-46].
Several HIV-1 proteins, such as surface glycoprotein
(gp120), Tat, Nef, Vpr, Vpu and PR, induce apoptosis by
triggering mitochondrial outer membrane permeabilization
(MOMP), thereby causing cell death [1-3,47]. The cyto-
toxic effect of HIV-1 PR in bacterial, yeast and human cells
has been attributed to its proteolytic activity [10-12]. How-
ever, precise mechanisms of either necrosis or apoptosis in
HIV-1 PR-expressing cells have not been uncovered. There
are two prominent molecular pathways of apoptosis: the
extrinsic pathway, also called the “death receptor pathway;”
and the intrinsic pathway, known as the “mitochondrial
pathway.” Most cell deaths in vertebrates proceed via the
intrinsic pathway, in which apoptosis is triggered by an
intracellular cascade of events in which MOMP regulated
by Bcl-2 family proteins plays a crucial role [4,48].Here, we show that the expression of HIV-1 PR in HEK-
293 or HeLa cells leads to the mitochondrial apoptotic
pathway. It was previously reported that HIV-1 PR in-
duces apoptosis via proteolytic cleavage of two proteins
involved in regulation of apoptosis, Bcl-2 and caspase 8
[11,18-20]. However, the HIV-1 PR-mediated cleavage of
the anti-apoptotic protein Bcl-2, affecting the balance of
anti- and pro-apoptotic proteins, was not confirmed by
other laboratories [12,18,22]. In our experiments, Bcl-2
protein was not cleaved by HIV-1 PR. Caspase 8 was
shown to be specifically processed by HIV-1 PR to a frag-
ment termed Casp8p41 [18]. Full-length caspase 8 cleaves
Bid to the C-terminal fragment tBid, the most important
link between the extrinsic and intrinsic apoptotic path-
ways. The tBid translocates to the mitochondria to
activate Bax/Bak channels and promote release of cyto-
chrome c. However, as the Casp8p41 fragment generated
by HIV-1 PR is catalytically inactive [19], the role of
Casp8p41 in the activation of Bid is unlikely. Indeed, no
Bid cleavage by HIV-1 PR was observed in our in vivo or
in vitro experiments. Similarly, we failed to detect clea-
vage of pro-caspase 8 (Figure 5). Recent studies of the
Casp8p41 fragment suggest that it could independently
induce apoptosis via its interaction with mitochondria,
resulting in rapid mitochondrial depolarization mediated
by Bax/Bak, cytochrome c release and activation of cas-
pase 9 and 3 [19,23,24]. These findings agree with our
results showing that HIV-1 PR activates caspase 9 both
in vivo and in vitro (Figure 5). The activation of caspase 9,
but not caspase 8, was also observed in HIV-1 infected
CD4+ lymphocytes [49].
Instead of proteolysis of pro- and/or anti-apoptotic
factors, we observed a direct impact of HIV-1 PR on
mitochondria. In the present study, we used several com-
plementary methods to confirm that HIV-1 PR is asso-
ciated with mitochondria: confocal microscopy showing
co-localization of HIV-1 PR with a mitochondrial marker,
detection of the presence of HIV-1 PR in mitochondria-
enriched subcellular fractions, and immunogold labeling
TEM. Although the mitochondrial localization of HIV-1
PR was rather unexpected, a previous report describes PR
activity in the cytoplasm as well as in the membrane
fraction of HIV-1-infected cells [9]. Active PR may also
be released during uncoating of the viral core, in which
it is present together with CA, NC, reverse transcrip-
tase, RNase H, integrase, Vpr and Nef [50]. CA, NC and
their fragments generated specifically by PR have been
detected in an early stage of cell infection by EIAV and
M-PMV [51,52].
Based on our results, we suggest that HIV-1 PR affects
the integrity of mitochondrial membrane(s), which sub-
sequently leads the cell to apoptosis. First, we visualized
HIV-1 PR in the mitochondria both by confocal micros-
copy and TEM. Immunogold TEM and experiments
Figure 6 BCA3 modulates p53 transcriptional activity. Analysis of bax-promoter-Luciferase reporter activation in response to dose of HA-BCA3
(a), HA-BCA3 with c-myc-HIV-1 PR(D25N) (b) transiently transfected in HEK-293 cells. (c) Endogenous levels of p53 and Bax in the extract of the
HEK-293 cells transfected with increasing amounts of HA-BCA3. (d) Subcellular fractionation and detection of endogenous p53 from HEK-293 cells
expressing increasing amounts of BCA3. (e) Protein control of cytosolic (C), mitochondrial (M) and nuclear (N) fractions purity: fractions were
purified as described in Material and Methods and analyzed using antibody against cytochrome c (mitochondrial marker) and lamin A (nuclear marker)
antibodies. (f) Mean percentage of apoptotic, Anexin-V positive cells expressing HIV-1 PR, BCA3 or both. Each experiment was performed in triplicate;
the mean values of three independent experiments (with standard deviation) are shown. The p value was insignificant (p < 0.4700295) between HIV-1
PR and BCA3, represented by columns 1 and 2, respectively. HIV-1 PR + BCA3 expression on apoptosis was statistically significant, characterized by
p < 0.0047547 and p < 0.0015748 for the cells expressing HIV-1 PR and BCA3, respectively.
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by proteinase K showed that a portion of HIV-1 PR is
localized below the mitochondrial surface, likely at the
inner membrane. Interestingly, this mitochondrial loca-
lization was independent of HIV-1 PR activity. Second,
we demonstrated that HIV-1 PR could efficiently process
Tom22, VDAC and ANT in vitro, which could lead to a
release of AIF and Hsp60 proteins in vivo. We therefore
assume that active HIV-1 PR can cleave mitochondrial
proteins, which would lead to loss of mitochondrial in-
tegrity. Third, the expression of HIV-1 PR caused loss of
in vivo mitochondrial potential, which is one distinctive
feature of the onset of programmed cell death. Ge-
nerally, membrane potential changes are caused by
opening of the mitochondrial permeability transition
pore (MPTP). Fourth, we observed expression of HIV-1
PR-activated caspase 9, which is usually recruited and
allosterically activated by the apoptosome formed by
released cytochrome c and APAF-1. Once initiated,
caspase 9 sets off the caspase cascade by processing
pro-caspase 3. Activated caspase 3 then cleaves several
cellular targets, including PARP and inhibitor of cas-
pase-activated DNase (ICAD) allowing DNA fragmenta-
tion by CAD (Figures 4 and 5).
We show here that HIV-1 PR interacts with BCA3 in
mitochondria and that coexpression of these proteins is
connected with enhanced transcriptional activity of p53
on the bax promoter and enhanced apoptosis induced
by HIV-1 PR. This finding is in very good agreement
with the data published by Genini et al. [49]. They found
that HIV-1 infection of CD4+ T cells led to p53 phos-
phorylation which is followed by increased level of p21,
Bax and p53 proteins. Moreover, Genini et al. also
demonstrated release of mitochondrial proteins cyto-
chrome c and AIF as well as detectable alteration of
mitochondrial membrane potential. Mitochondrial loca-
lization of BCA3 was described in association with two
proteins, p73 and AIF [31,32]. The association of p73
and BCA3 in mitochondria leads to cell death [31].
Sastri et al. showed that BCA3 protein is up-regulated in
response to oxidation stress and that it interacts with
mitochondrially localized AIF [32]. It remains unclear
whether the interaction of BCA3 with the HIV-1 PR
occurs directly or whether it is mediated by some other
protein. If the latter is the case, it is plausible that AIF
fulfills the role of the interaction mediator. Our observa-
tion suggests that BCA3 could function as molecular




All DNA manipulations were carried out using standard
subcloning techniques, and plasmids were propagated inE. coli DH5α. All newly created constructs were verified
by DNA sequencing. The full-length and spliced forms of
the genes encoding human BCA3 and BAX were obtained
by reverse transcription of total RNA from HeLa cells and
cloned into pCMV-HA/c-myc (Clontech) or pET22b,
resulting in HA-BCA3, c-myc-BCA3 or BAX vectors,
respectively. PCR fragments encoding M-PMV or HIV-1
protease (PR), their inactive forms (D26N, D25N) or HIV-1
protease precursor (PRO) were subcloned into plasmids for
mammalian (pCMV-HA/c-myc) or bacterial (pET22b) ex-
pression, resulting in vectors c-myc-M-PMV PR17 (D26N),
c-myc-M-PMV PR12 (D26N), c-myc-HIV-1 PR, HA-HIV-1
PR, c-myc-HIV-1 PR (D25N), HA-HIV-1 PR (D25N)c-myc-
HIV-1 PRO, and HIV-1 PR pET22b. Point mutations and
deletions within BCA3, HIV-1 PR, and BAX genes were
introduced by two-step PCR mutagenesis using primers
carrying the desired mutations and suitable restriction
sites. The PCR fragments were digested with appropriate
restriction enzymes and ligated into HA/c-myc-pCMV or
pET22b.
The pSAX2 vector, which encodes HIV-1 proviral DNA
with deletion of the env gene, was kindly provided by
Dr. J. Luban. The pGL3-bax-luc luciferase reporter vector
was kindly provided by Prof. L. Tuosto. The pDsRed2-
Mito mammalian expression vector, which encodes a
fusion of Discosoma sp. red fluorescent protein (DsRed2)
and the mitochondrial targeting sequence from subunit
VIII of human cytochrome c oxidase, was purchased from
Clontech. Further details of the cloning strategy and full
sequences of all PCR primers can be obtained from the
authors upon request.
Cell lines and protein expression
HEK-293 and HeLa cells were grown in Dulbecco’s mo-
dified Eagle medium (DMEM, Sigma) supplemented with
10% fetal bovine serum (Sigma) and 1% L-glutamine
(PAA) at 37°C under 5% CO2. Typically, cells were plated
at a density of 2–5 × 105 cells/ml one day before trans-
fection. The following day, cells were transfected with
the appropriate plasmid using X-tremeGENE HP DNA
Transfection Reagent (Roche) according to the manufac-
turer’s instructions. The cells were grown for 6–48 h post-
transfection and washed with phosphate-buffered saline
(PBS). Further processing depended on the type of experi-
ment. A stable HEK-293 cell line expressing HA-BCA3
was prepared as described in [33].
Expression and purification of HIV-1 PR
HIV-1 PR was purified as previously described [53].
Briefly, the vector HIV-1 PR pET22b was introduced in
E.coli BL21 (DE3) RIL cells (Invitrogen) and HIV-1 PR
was produced in the form of inclusion bodies. The inclu-
sion bodies were isolated and resuspended in 60% acetic
acid. The suspension was diluted with water and dialyzed
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glycerol, 1 mM EDTA, 0.05% ME, pH 5.8). The refolded
protein was then purified by ion-exchange chromato-
graphy (Mono S 5/50 GL, GE Healthcare). The appro-
priate fractions were aliquoted and frozen at −20°C.
Western blotting
Proteins were resolved by reducing SDS-PAGE and
blotted onto a nitrocellulose membrane. To prevent
nonspecific interactions, the membrane was blocked with
Blocking Solution (Thermo Scientific) and then incubated
with primary antibody for 2 h to overnight. After washing
with PBS (3×), the membrane was incubated with HRP-
conjugated secondary antibody for 1–2 h at 4°C. The
antigen-antibody complexes were detected by West Femto
Chemiluminescent Substrate (Thermo Scientific) using a
LAS-2000 imager. The following antibodies were pur-
chased from Sigma-Aldrich: monoclonal anti-mitochon-
drial protein (MTC02) and rabbit anti- COX IV antibodies
and anti-VDAC1/Porin from Abcam; monoclonal anti-
HA peroxidase conjugate clone HA-7, EZview Red Anti-
HA Affinity Gel, anti-alpha-tubulin (B512), anti-C11orf17
(BCA3), anti-HA-TRITC, anti-HA clone HA-7 FITC,
anti-c-myc FITC, and anti-p53 (PAb1801) antibodies and
rabbit polyclonal anti-HSPD1, anti-AIF, anti-Tomm22,
anti-c-myc, anti-VDAC/Porin, anti-CANX, and anti-BCA3
antibodies. The monoclonal anti-c-myc HRP, anti-c-myc
(9E10), anti-Bax (2D2), and anti-HA (F-7) antibodies and
goat anti-caspase 8p18(C-20) and anti-BCA3 (N-12) anti-
bodies were purchased from Santa Cruz. The following
antibodies were purchased from Cell Signaling; rabbit
anti-Bcl2, anti-PARP, anti-Bid, anti-caspase 9, anti-Bax,
and anti–acetyl-p53 (Lys382) antibodies and rabbit mono-
clonal anti-Bak (D2D3), anti-Bax (D2E11), anti-COXIV
(3E11), and anti-cleaved caspase 8 (Asp391) antibodies
and monoclonal anti-caspase-8 (1C12) antibody. Mono-
clonal anti-cytochrome C and anti-PKA(C) antibodies
were purchased from BD Pharmingen; and rabbit anti-
ANT antibody from LSBio. All secondary antibodies
(anti-rabbit IgG, anti-mouse IgG) were HRP- (Sigma)
or gold- (British Biocell) conjugated.
Co-immunoprecipitation
Co-immunoprecipitation was carried out as previously
described [54]. Briefly, HEK-293 or HeLa cells were grown
on 60 mm plates and co-transfected with HA-BCA3,
c-myc-M-PMV PR17(D26N), c-myc M-PMV PR12(D26N)
or c-myc-HIV-1 PR(D25N). After 48 h, the cells were
washed 1× with PBS and lysed in 300 μl CO-IP buffer B
(20 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA,
1 mM DTT, 0.1 mM MgCl2, 0.5% NP-40) containing Halt
Protease Inhibitor Mix (Thermo Scientific) for 30 min on
ice. A 1/5 of the total cell lysate sample was used for
Western blot analysis. The rest of the cell lysate wascleared by centrifugation and diluted with 1 200 μl CO-IP
A buffer (20 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1 mM
EDTA, 1 mM DTT, 0.1 mM MgCl2). Primary antibody
[monoclonal anti-c-myc (Santa-Cruz), rabbit anti-c-myc
or EZview Red Anti-HA Affinity Gel (Sigma)] was added
to the cell extract and incubated overnight at 4°C. Optio-
nally, 20 μl Protein-A/G-Sepharose beads were added, and
after 2 h incubation at 4°C, the immunoprecipitates were
collected by centrifugation. The pellets were washed 3×
with CO-IP buffer and then 1× with PBS. Proteins were
resolved by SDS-PAGE and analyzed by Western blotting.
Immunoprecipitation from mitochondrial and cytosolic
fractions
HEK-293 cells (4×105cells/ml) were seeded on 2×100
mm plates and co-transfected with HA-BCA3pCMV
and c-myc-HIV-1 PR(D25N). After 48 h, the cells were
washed 1× with PBS and 1/20 of the cells was resus-
pended in PLB and used as total cell lysate sample for
Western blot analysis. The rest of the cells was aliquoted:
1/4 was resuspended in 300 μl CO-IP buffer B, and immu-
noprecipitation was carried out as described above; 3/4
were resuspended in 0.5 ml homogenization medium HB
(250 mM sucrose, 1 mM EDTA, 1 mM EGTA, 20 mM
HEPES-NaOH, 10 mM KCl, 1.5 mM MgCl2, pH 7.4)
supplemented with Halt Protease Inhibitor Mix (Thermo
Scientific) and homogenized by 50 strokes in a Dounce
homogenizer. The cell lysate was centrifuged for 10 min
at 1000 × g. The pellet was resuspended in 0.5 ml HB, re-
homogenized by 30 strokes in a Dounce homogenizer, and
centrifuged for 10 min at 1 000 × g. Both supernatants
were combined and centrifuged at 17 000 × g for 15 min.
NP-40 and NaCl were added to the supernatant (cytosolic
fraction) to final concentrations of 0.1% and 150 mM,
respectively. The mitochondrial pellet was washed 1× with
400 μl HB and resuspended in 1 ml of CO-IP buffer A
supplemented with 0.1% NP-40. 100 μl aliquots of both
cytosolic and mitochondrial fractions were mixed with
PLB and used as total cytosolic and mitochondrial lysate
samples for Western blot analysis. 900 μl aliquots of both
samples were used for immunoprecipitation using anti-
c-myc and anti-HA antibodies, as described above.
Subcellular fractionation and mitochondria isolation
To obtain a crude mitochondrial fraction, cells (1 × 108
cells/ml) were washed with PBS, pelleted by centrifu-
gation at 300 × g for 5 min and frozen at −70°C. The cell
pellet was resuspended in 1 ml homogenization medium
HB supplemented with Halt Protease Inhibitor Mix
(Thermo Scientific) and homogenized by 50 strokes in a
Dounce homogenizer. The cell lysate was centrifuged for
10 min at 1 000 × g. The pellet was resuspended in 1 ml
HB, re-homogenized by 30 strokes in a Dounce homo-
genizer, and centrifuged for 10 min at 1 000 × g. Both
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fraction was obtained by centrifugation at 17 000 × g for
15 min. The pellet containing crude mitochondria was
washed with HB (1×), resuspended in the same buffer and
used for subsequent experiments. The remaining super-
natant was subjected to ultracentrifugation at 100 000 × g
for 1 h at 4°C, and the microsome-containing pellet was
analyzed by Western blotting [55]. Mitochondria were
further purified by centrifugation in a discontinuous gra-
dient of Optiprep according to the manufacturer’s in-
structions (http://www.axis-shield-density-gradient-media.
com). Briefly, the crude mitochondrial fraction was resus-
pended in 1.4 ml HB and 3.6 ml solution D [5 volumes
of 50% iodixanol and 1 volume of solution C (0.25 M
sucrose, 6 mM EDTA, 120 mM HEPES-NaOH, pH 7.4)].
This suspension was overlaid with 3.6 ml of each of two
gradient solutions (with densities of 1.175 g/ml and
1.079 g/ml) and centrifuged at 50 000 × g for 3 h in a
Beckman SW41 rotor. The gradient was collected in
1 ml fractions and analyzed by Western blotting. To
recover purified mitochondria, the appropriate gradient
fraction(s) was diluted by HB (1:3) and centrifuged at 17
000 × g for 15 min. Pelleted mitochondria were washed
with HB and resuspended in HB solution. In experiments
in which nuclear and mitochondrial fractions were isolated,
the NE-PER Nuclear Extraction Kit and Mitochondrial
Isolation Kit (Thermo Scientific), respectively, were
used.
HIV-1 PR treatment of cell lysates
HEK-293 or HeLa cells, optionally transfected with HIV-1
Gag, c-myc-HIV-1 PR and HA-BCA3, were washed with
PBS, pelleted by centrifugation at 300 × g for 5 min and
frozen at −70°C. The cell pellet was resuspended in 500 μl
solution B (60 mM MES, pH 6.5, 120 mM NaCl, 0.1%
NP-40) and homogenized by 50 strokes in a Dounce
homogenizer. The cell lysate was centrifuged for 10 min
at 1 000 × g. The pellet was resuspended in 500 μl 60 mM
MES, pH 6.5, containing 120 mM NaCl, homogenized by
30 strokes in a Dounce homogenizer and centrifuged for
10 min at 1 000 × g. Both supernatants were combined
and incubated with recombinant HIV-1 PR (1.25 μM final
concentration), optionally in the presence of ritonavir
(Sigma) (4 μM final concentration) or calpain inhibitor I
(Sigma) (33–100 μM final concentration) at 37°C. The
reaction was stopped by addition of 2× protein loading
buffer (PLB). Samples were separated on 12 or 15% SDS-
PAGE and analyzed by Western blotting.
HIV-1 PR treatment of purified mitochondria
Freshly isolated mitochondria were diluted in SB buffer
(200 mM sucrose, 10 mM HEPES-NaOH, pH 7.4, 2 mM
NaCl, 5 mM KH2PO4, 2 mMMgCl2) to a final protein con-
centration of 1 mg/ml. Various amounts of recombinantHIV-1 PR (4 μM storage concentration) in the presence
or absence of ritonavir (4 μM final concentration) were
added, and incubation proceeded overnight at room tem-
perature. The reaction was stopped by addition of 2× PLB.
Proteins were separated by 12-15% SDS-PAGE and ana-
lyzed by Western blotting. In the experiments studying
the release of the mitochondrial protein, the mitochon-
dria were after incubation with HIV-1 PR centrifuged
for 16 000 × g for 10 min at 4°C. The selected proteins
from the supernatant were analyzed by Western blot.
In vitro preparation and cleavage of Bax protein
The p21 and p18 forms of Bax protein were prepared by
TNT Quick Coupled Transcription/Translation System
(Promega) according to the manufacturer’s instructions.
Briefly, 40 μl TNT Quick Master Mix was mixed with
1 μg plasmid DNA together with 2 μl 35S methionine
(10 mCi/ml) in nuclease-free water to a final volume of
50 μl. The mixture was incubated for 3 h at 30°C. Buffer
containing 60 mM MES, 120 mM NaCl, pH 5.5, (50 μl)
was added to each sample, followed by treatment with
HIV-1 PR (1.25 μM final concentration) in the presence
or absence of ritonavir (8 μM final concentration) for
various time at room temperature. The reaction was
stopped by addition of 2× PLB. HIV-1 PR activity was
monitored by cleavage of purified HIV-1 CANC protein.
Samples were resolved by 15% SDS-PAGE and visualized
by autoradiography.
Proteinase K digestion of isolated mitochondria
The basic experimental procedure was adapted from
previously described methods [56,57]. Freshly isolated
mitochondria from 0.5 × 108 HEK-293 cells co-trans-
fected with c-myc-HIV-1 PR(D25N) and HA-BCA3 were
resuspended in 350 μl homogenization buffer without
protease inhibitors, and protein concentration was as-
sessed by Bradford assay. Fresh mitochondrial samples
(300 μg/100 μl) were incubated (i) alone, (ii) in the pre-
sence of proteinase K (Sigma) (0.14, 1.4 or 14 μM final
concentration) or (iii) in the presence of Triton X-100
(1% final concentration) and proteinase K (0.14, 1.4 or
14 μM final concentration) for 10 or 60 min on ice. The
reaction was stopped by the addition of 6× PLB, and
samples were analyzed by Western blotting.
Luciferase assay
HEK-293 cells were grown in a 24-well plate and were
transfected with the appropriate vectors. Cells were lysed
in Glo™ Lysis Buffer (Promega) 48 h post-transfection,
and luciferase activity was determined by One-Glo™
Luciferase Assay System (Promega) using a fluorescence
reader. Relative luciferase activity was corrected for dif-
ferences in transfection efficiency by co-transfection
with a GFPpCMV construct followed by fluorescence
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plicate; at least three independent experiments were
performed.
Flow cytometry analysis of dead and apoptotic cells
Determination of dead cells was adapted from the proce-
dure described by Vermes et al. [58]. HeLa cells growing
in six-well plates were transfected with c-myc-HIV-1 PR at
various times, and the cells were harvested at 12, 18, 24
and 48 h post-transfection by standard trypsinization [59].
The cells were gently washed twice in PBS (300 × g,
5 min), resuspended in annexin-binding buffer and labeled
with FITC Alexa Fluor® 488 annexin V and propidium iod-
ide (PI) according to the manufacturer’s protocol for Dead
Cell Apoptosis Kit (Invitrogen). Analyses were performed
by flow cytometry using BD LSR Fortessa with BD FACS-
Diva software. Ten thousand events were collected for
each sample.
Flow cytometry analysis of mitochondrial membrane
potential (ΔΨm)
The protocol was adapted from previous reports [60,61].
HEK-293 cells were seeded in 12-well plates overnight
and transfected with 0.5, 1 or 2 μg/ml c-myc-HIV-1PR.
Changes in ΔΨm were determined by JC-1 fluoro-
chrome (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethyl benzi-
midazolylcarbocyanine iodide) stored in DMSO (Sigma)
24 h post-transfection. The cells were incubated in
DMEM containing 12.5 μg/ml JC-1 at 37°C under 5%
CO2 for 45 min. Cells incubated with 400 μM CCCP (car-
bonyl cyanide 3-chlorophenylhydrazone) stored in DMSO
(Sigma) for 2 hours were used as a positive control. After
incubation, the samples were washed twice with cold PBS,
and cell pellets were resuspended in 500 μl PBS and
immediately analyzed by flow cytometry using BD LSR
Fortessa. Healthy cells containing red JC-1 aggregates
were detected in the FL 2 channel, while green JC-1
monomers in apoptotic cells were monitored in the FL1
channel (FITC). Ten thousand events were collected for
each sample.
Fluorescence microscopy
HEK-293 or HeLa cells at a density of 1 × 105 cells/ml
were plated on a glass coverslip placed in a 6-well plate
and incubated in DMEM medium supplemented with
10% FBS (Sigma) and 1% L-glutamine (PAA) at 37°C
and 5% CO2. The following day, the cells were trans-
fected with appropriate plasmid DNA using FuGENE
HD Transfection Reagent (Roche) according to the
manufacturer’s protocol. 48 h post transfection, the cells
were washed with PBS, fixed with 4% formaldehyde and
incubated for 30 min at room temperature. The cells
were washed 2× with PBS and incubated 10 min in 0.4%
Triton X-100, followed by 2 × 5 min incubation with0.1% Triton X-100. The cells were then incubated with
primary fluorescently labeled antibodies for 60 min at
room temperature, washed 2× with PBS and mounted
using mounting media (Vectashield, Vector Labora-
tories), containing or not DAPI (4′,6-diamidine-2-phenyl
indole) at a final concentration of 1.5 μg/ml. The sam-
ples were then imaged using a laser scanning confocal
microscope (Leica) or Olympus IX 81 microscope.
Immunoelectron microscopy
Cell preparation
HEK-293 cells were fixed for 30 min at 4°C in 0.1 M
PIPES, pH 7.5, containing 2% formaldehyde and 0.1%
glutaraldehyde. After washing, the samples were gradually
dehydrated at 4°C in 30%, 50%, 70%, 90% aqueous ethanol
(10 min in each bath) and finally twice in anhydrous
ethanol for 10 min. After dehydration, the samples were
embedded in LR White. The cells were infiltrated at 4°C
in a 1:2 (v/v) mixture of LR White and ethanol for 15 min,
a 1:1 (v/v) mixture for 30 min and a 2:1 (v/v) mixture for
30 min, followed by overnight incubation in pure resin at
4°C. Polymerization was carried out at 18°C under UV
light for 72 h.
Immunogold labeling
Ultrathin sections (90 nm) were mounted on parlodion-
coated nickel grids. The grids were washed briefly in water
and incubated in blocking buffer [1% BSA (w/v) in PBS,
pH 7.4] containing 10% normal goat serum (v/v) for
25 min. The grids were then incubated in buffer A [0.5%
BSA (w/v), 0.05% (v/v) TWEEN 20 in PBS, pH 7.4]
containing monoclonal antibody against HA (Santa Cruz)
or VDAC (Sigma), diluted 1:100, for 2 h at room tem-
perature. The grids were washed three times in buffer A
and then transferred to a droplet of goat anti-mouse
IgG conjugated to 10 nm gold particles (British Biocell),
diluted 1:25 in buffer A, and incubated 1 h at room
temperature. After washing in buffer A, the grids were
stained with uranyl acetate and examined with a JEOL
JEM 1200EX electron microscope.
Additional file
Additional file 1: Figure S1. Association of HIV-1 PR, its various forms
and BCA3 with mitochondrial membranes. (a) Detailed analysis of the
composition of mitochondrial fractions 1–12 from HeLa cells expressing HIV-1
PR(D25N) and BCA3. Fractions from Optiprep gradient ultracentrifugation of
HeLa cell lysates were analyzed by Western blot using the antibodies
indicated. (b) Schematic representation of HIV-1 PR constructs used in this
work. 25DTG27 is the active site triplet; TFP is the transframe octapeptide
that forms the native N-terminal flanking sequence together with p6.
(c) Mitochondrial localization of HIV-1 PR variants. HEK-293 cells were
transfected with indicated constructs expressing various forms of HIV-1 PR,
optionally in the presence of ritonavir (final concentration of 10 μM).
Mitochondrial fractions 1–12 from the Optiprep gradient were analyzed by
Western blotting. (d) Detection of BCA3 and HIV-1 PR in ER fractions.
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expressing BCA3 and HIV-1 PR (D25N), described in Material and Methods,
was subjected to ultracentrifugation at 100 000 × g for 1 h at 4°C, and the
microsome-containing pellet, highly enriched in ER bur largely devoid of
mitochondria [55] was analyzed by Western blotting using anti-calnexin
antibody as a marker of ER. (e) Immunoprecipitation of HIV-1 PR(D25N) and
HIV-1 PRO(D25N) from BCA3 stable transfected cell line (D1): D1 cells were
transfected with c-myc-HIV-1 PR (D25N) and c-myc-HIV-1 PRO (D25N). 48 h post
transfection the cells were lysed and 1/10 of the lysate was analyzed using
anti-c-myc (upper panel) and anti-HA (lower panel) antibodies. The rest of cell
lysate was divided into two halves: one half was immunoprecipitated with
anti-c-myc and the second with anti-HA antibodies. Precipitates were blotted
and developed with anti-c-myc (upper panel) or anti-HA (lower panel)
antibodies.
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